Caloric restriction: the CALERIE-2 trial and what we know about humans

Caloric restriction (CR), reducing intake below what's needed to maintain weight, while maintaining nutritional adequacy, extends lifespan in essentially every species tested, from yeast to non-human primates. Whether and how this translates to humans has been one of the longest-running questions in longevity research.

CALERIE-2 (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) is the largest and best-controlled human trial of moderate CR in non-obese adults. Its results have shaped the modern understanding.

What CALERIE-2 was#

A multi-centre RCT enrolling 218 non-obese adults (BMI 22–28) aged 21–50. Participants were randomised to:

• CR group: target 25% caloric restriction for 2 years (actual achieved was ~12%; adherence is harder than intent)
• Control: ad libitum eating

Outcomes were biomarkers of cardiometabolic and ageing-related processes. The trial was not powered to show mortality or hard-endpoint differences in 2 years.

What CALERIE-2 found#

Cardiometabolic markers. Significant improvements in blood pressure, LDL cholesterol, triglycerides, fasting insulin, and HOMA-IR in the CR group. Effect sizes were modest but consistent.

Body composition. CR group lost ~10% body weight; ~71% of weight loss was fat mass; lean mass loss was modest.

Resting metabolic rate. Decreased proportionally more than expected from weight loss, suggesting metabolic adaptation beyond simple energy balance.

Quality of life. No significant adverse psychological effects in the CR group; some improvements in mood and sleep.

Inflammatory markers. Reductions in hs-CRP and TNF-α.

Thyroid function. Modest decline in T3, reflecting adaptive metabolic slowing.

Bone mineral density. Some loss in CR group, particularly at hip (clinically modest but real).

Epigenetic age. Subsequent analysis (Waziry et al. 2023, senior author Belsky) of CALERIE-2 samples using the DunedinPACE DNA-methylation algorithm showed a slowed pace of biological ageing in the CR group, though other DNA-methylation clocks (PhenoAge, GrimAge) did not change significantly.

What CALERIE-2 didn't establish#

Human lifespan extension. The trial wasn't long enough or powered to detect mortality differences. The biomarker improvements are suggestive of plausible longevity benefit; they aren't proof.

That CR is necessary for these benefits. Many of the same improvements occur with weight loss from caloric restriction in overweight adults; whether the additional benefit in non-obese CR is meaningful is debated.

Optimal dose. CALERIE-2 was designed for 25%; achieved 12%. Whether deeper CR would produce larger or different effects in non-obese adults isn't known from this trial.

Whether CR effects translate to populations. The trial was in young, healthy, motivated adults. Effects in older adults or those with comorbidities aren't directly tested.

The non-human primate evidence#

Two long-term rhesus monkey CR trials produced apparently contradictory results:

• Wisconsin (Colman et al.): significant lifespan and healthspan extension
• NIA (Mattison et al.) — initially showed no significant lifespan effect, though subsequent analyses found benefits in adult-onset CR

The reanalysis suggests both trials show benefit, with timing and dietary composition mattering. The macaque data are the most relevant non-human evidence for primate longevity effects of CR.

CR vs intermittent fasting vs time-restricted eating#

These overlap but aren't identical:

• CR (CALERIE-style): chronic moderate restriction; reduced total weekly calories
• Intermittent fasting / 5:2: alternating fast / feast days; total weekly calories may or may not be reduced
• TRE (16:8): restricted eating window; total daily calories may or may not be reduced

Trials comparing matched-calorie versions show mostly similar effects on weight and metabolic markers. The "magic" of any one pattern over equivalent caloric reduction isn't strongly supported.

Practical implications#

For most readers:

• Sustained CR is hard. CALERIE-2 participants achieved ~12% restriction with substantial behavioural support; most people don't sustain this without intervention.
• Most of the cardiometabolic benefit appears at modest restriction. Going from 100% to 88% intake captures much of the trial benefit.
• Bone density warrants attention in long-term CR.
• The longevity benefit in humans is still inferred from biomarkers, not directly measured.

For someone interested in the CR approach, modest sustained restriction with adequate protein and resistance training is the safer pattern than aggressive caloric deficit.

Where the longevity claims overrun#

"CR extends lifespan in humans." Not directly demonstrated; inferred from biomarkers, animal data, and observational studies of voluntary CR practitioners.

"More restriction = more benefit." The biomarker improvements may plateau at modest restriction; severe restriction adds bone, hormonal, and quality-of-life costs.

"CR can substitute for exercise." No. Most CR longevity trials in animals are sedentary controls; humans need both.

Who shouldn't restrict#

• Underweight (BMI <22)
• History of disordered eating
• Pregnancy or breastfeeding
• Children and adolescents
• Older adults with sarcopenia or frailty
• People with active medical conditions requiring stable nutrition

What we'd actually say#

CALERIE-2 is the most rigorous human trial of moderate caloric restriction and shows that ~12% sustained restriction in non-obese adults produces measurable cardiometabolic improvements and slowed epigenetic ageing. These are real, replicated findings.

The translation to human lifespan extension remains inferred. The dose-response is uncertain. The cost-benefit calculation depends on individual circumstances.

For someone with overweight or metabolic markers slightly out of range, sustained moderate caloric reduction with adequate protein and resistance training delivers most of the trial benefits.

For someone of normal weight contemplating sustained CR purely for longevity, the trade-offs (bone density, hormonal effects, quality of life) deserve careful consideration. The boring alternative (Mediterranean-style dietary pattern, adequate protein, resistance training, aerobic exercise, good sleep) captures much of the same biology without the sustained restriction.

When to talk to a clinician#

• Considering sustained CR in non-obese state
• History of eating disorder
• Significant weight loss without medical guidance
• BMI under 22
• Sustained CR + osteoporosis risk factors
• Combining CR with intensive exercise (low energy availability concerns)
• Children or adolescents in your household considering restriction